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A B S T R A C T   
Non-Alcoholic Fatty Liver Disease (NAFLD), a progressive liver disease that is closely associated with obesity, 
type 2 diabetes, hypertension and dyslipidaemia, represents an increasing global public health challenge. There 
is significant variability in the disease course: the majority exhibit only fat accumulation in the liver but a 
significant minority develop a necroinflammatory form of the disease (non-alcoholic steatohepatitis, NASH) that 
may progress to cirrhosis and hepatocellular carcinoma. At present our understanding of pathogenesis, disease 
natural history and long-term outcomes remain incomplete. There is a need for large, well characterised patient 
cohorts that may be used to address these knowledge gaps and to support the development of better biomarkers 
and novel therapies. 
The European NAFLD Registry is an international, prospectively recruited observational cohort study that 
aims to establish a large, highly-phenotyped patient cohort and linked bioresource. Here we describe the in-
frastructure, data management and monitoring plans, and the standard operating procedures implemented to 
ensure the timely and systematic collection of high-quality data and samples. Already recruiting subjects at 
secondary/tertiary care centres across Europe, the Registry is supporting the European Union IMI2-funded 
LITMUS ‘Liver Investigation: Testing Marker Utility in Steatohepatitis’ consortium, which is a major interna-
tional effort to robustly validate biomarkers that diagnose, risk stratify and/or monitor NAFLD progression and 
liver fibrosis stage. The European NAFLD Registry has the demonstrable capacity to support research and bio-
marker development at scale and pace.   
1. Introduction 
Non-alcoholic fatty liver disease (NAFLD) is the most common 
chronic liver disease worldwide and represents a major global public 
health challenge. It is characterised by the increased accumulation of 
hepatic fat (> 5%) and is closely linked with the presence of the me-
tabolic syndrome and its components: obesity, type 2 diabetes mellitus, 
hypertension and dyslipidaemia. [1,2] The exclusion of other causes of 
Fig. 1. Map of recruiting sites into the European NAFLD registry. 
The European NAFLD Registry is actively recruiting at sites across Europe using a ‘hub-and-spoke’ model. National lead sites (red), recruiting centres (blue). 
Additional recruitment is also taking place at selected sites in USA. (For interpretation of the references to colour in this figure legend, the reader is referred to the 
web version of this article.) 
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fat accumulation such as excessive alcohol consumption is traditionally 
part of the disease definition although a recently proposed revised 
nomenclature, metabolic-dysfunction associated fatty liver disease 
(MAFLD), places emphasis on the pre-eminence of metabolic-dysfunc-
tion. [3] NAFLD is a spectrum of progressive liver disease comprising 
steatosis (non-alcoholic fatty liver, NAFL), in which excessive hepatic 
fat is present, and non-alcoholic steatohepatitis (NASH), a necroin-
flammatory form of the condition marked by histological inflammation 
and hepatocyte ballooning that leads to progressive liver fibrosis. 
NAFLD is a cause of significant morbidity and mortality; left untreated, 
fibrosis may progress to cirrhosis and can result in end-stage liver dis-
ease or hepatocellular carcinoma (HCC). [4–6] 
The prevalence estimates of NAFLD vary widely according to the 
modality used to detect NAFLD and the geographical area. A recent 
meta-analysis estimated the global prevalence of NAFLD to be 25% of 
adults, with the highest estimates in the Middle East and South America 
(32% and 31%, respectively) and the lowest estimates in Africa (14%); 
the estimates for Asia, the USA, and Europe were 27%, 24% and 23%, 
respectively. [2,7] Modelling studies predict a steady increase in dis-
ease incidence in China, France, Germany, Italy, Japan, Spain, United 
Kingdom, and United States that is accompanied by an increase in liver 
transplantation, HCC and mortality from liver and non-liver-related 
causes. [8] The associated economic burden is substantial and, without 
a concerted public health response, will continue to increase as more 
people are affected. [9–11] 
NAFLD is characterised by substantial inter-patient variability in 
terms of severity and rate of progression. [12] Despite there being a 
large at-risk population, only a minority experience significant mor-
bidity. The factors that determine transition from NAFL to NASH, and 
subsequent progression of fibrosis to cirrhosis are incompletely under-
stood. Thus, there are key knowledge gaps, in particular limited clarity 
on modifiers of disease natural history and an incomplete under-
standing of disease pathophysiology. These issues contribute to the lack 
of tractable non-invasive biomarkers of disease severity that hinder the 
diagnosis, risk stratification and monitoring of patients, and the ab-
sence of approved pharmacological therapies. 
Although many people have NAFLD, few are sufficiently well 
characterised for their data to be tractable in research. This is because 
histopathological examination of liver tissue is required to differentiate 
NAFL from NASH, grade steatohepatitis activity and accurately stage 
fibrosis. [5] However, liver biopsy is not widely utilised outside spe-
cialist centres as it is resource-intensive and carries a small but appre-
ciable risk of complications. Therefore, a broad collaborative effort is 
required to pool sufficient data from comprehensively phenotyped pa-
tients at specialist centres to assemble an adequately sized cohort that 
may be leveraged to support research. The European NAFLD Registry 
(ENR) is an innovative, international patient registry with an associated 
bioresource that is assembling a large, well-characterised patient cohort 
specifically to support translational and discovery science. 
Table 1 
Current recruitment sites by country.      
Country National lead investigator Site name Site PI  
UK Quentin Anstee Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust Quentin Anstee 
Barts Health NHS Trust, London William Alazawi 
Hull University Teaching Hospitals NHS Foundation Trust Lynsey Corless 
Oxford University Hospitals NHS Foundation Trust Jeremy Cobbold 
Portsmouth Hospitals NHS trust Joanna Dowman 
Cambridge University Hospitals NHS Foundation Trust Mike Allison 
University Hospitals Birmingham NHS Foundation Trust Philip Newsome 
Nottingham University Hospitals NHS Trust Guruprasad Aithal 
University Hospitals Plymouth NHS Trust David Sheridan 
Queen Elizabeth Hospital, Gateshead Dina Mansour 
City Hospitals Sunderland, Sunderland Harriet Mitchison 
St Georges Hospital, London Daniel Forton 
Leeds Teaching Hospitals NHS Trust Richard Parker 
France Vlad Ratziu Assistance Publique – Hôpitaux de Paris Vlad Ratziu 
Angers University Hospital Jerome Boursier 
Italy Elisabetta Bugianesi University of Torino Elisabetta Bugianesi 
University of Ancona Gianluca Svegliati- Baroni 
Università Cattolica del Sacro Cuore of Rome Luca Miele 
University of Palermo Salvatore Petta 
University of Milano Luca Valenti 
Germany Andreas Geier Jörn Schattenberg University of Wurzburg Andreas Geier 
University Medical Centre Mainz Jörn Schattenberg 
Charité University Hospital, Berlin Münevver Demir 
Hannover Medical School Heike Bantel 
Uniklinik RWTH Aachen Christian Trautwein 
Spain Manuel Romero-Gomez Andalucia Health Service, Seville Manuel Romero-Gomez 
Puerta de Hierro Hospital, Majadahonda Jose Luis Calleja 
Vall d'Hebron Hospital, Barcelona Salvador Augustin 
Biodonostia Research Institute-Donostia University Hospital, San Sebastián Jesús Banales & Rocio Aller 
University Hospital Valladolid, Valladolid Rocio Aller 
Marques de Valdecilla Hospital, Santander Javier Crespo 
USA Stephen Harrison Pinnacle Clinical Research, San Antonio, Texas Stephen Harrison 
Portugal Helena Cortez Pinto University of Lisbon Helena Cortez Pinto 
Belgium Sven Francque University Hospital Antwerp Sven Franque 
Netherlands Adriaan Holleboom Amsterdam University Medical Centre Adriaan Holleboom & Ulrich Beuers 
Sweden Mattias Ekstedt Linköping University Mattias Ekstedt 
Karolinska Institutet, Stockholm Hannes Hagström 
Greece George Papatheodoridis National and Kapodistrian University, Athens George Papatheodoridis 
Finland Hannele Yki- Jarvinen Helsinki University Hannele Yki- Jarvinen 
Switzerland Jean-Francois Dufour Bern University Jean-Francois Dufour 
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2. Methods 
2.1. Overview 
The European NAFLD Registry is a prospectively recruited, inter-
national observational study to assemble a cohort of highly-phenotyped 
patients across the full spectrum of NAFLD that will facilitate cross- 
sectional and longitudinal analyses (clinicaltrials.gov registration 
NCT04442334) [13]. The comprehensive dataset includes clinical in-
formation, liver histopathology and imaging data derived from 
healthcare records during routine medical care and is supplemented by 
lifestyle and quality of life data, as well as biological sample collection. 
The European NAFLD Registry infrastructure hosts a uniform da-
taset of patient level data that is split into two distinct sub-sections:  
i. The ‘Metacohort’: comprises prospectively recruited NAFLD cases 
that consented to participate during recruitment for European stu-
dies into NAFLD pathogenesis conducted from 2010 to December 
2017 (i.e. the FP7-FLIP, H2020-EPoS and HEPAmet cohorts) 
[14–16], plus cases with compatible consent and data collection 
processes derived from previous investigator-led single-centre co-
horts. Data from these cohorts have been integrated into a single 
dataset whilst maintaining data quality and retaining knowledge of 
the source.  
ii. The ‘LITMUS Study Cohort’: comprises prospectively recruited 
NAFLD cases acquired since 1st January 2018 as part of the IMI2- 
funded LITMUS project [17]. Recruitment is ongoing across Europe 
according to a common Master Study Protocol with a comprehen-
sive data monitoring process and standard operating procedures for 
sample handling implemented. Recruitment is currently active 
at > 25 centres in 13 countries (Fig. 1 and Table 1.) 
Patients with that are enrolled into the European NAFLD Registry 
will be followed-up for up to 10-years to allow assessment of long-term 
outcomes. 
2.2. Objectives 
The primary objective of the European NAFLD Registry observa-
tional study is to assemble a ‘real-world’ cohort of well-characterised 
patients across the full spectrum of NAFLD and to collect associated 
clinical information, biological samples and imaging data for cross- 
sectional and longitudinal analyses to support research into disease nat-
ural history. 
Key secondary objectives are to support research addressing the 
pathophysiology of NAFLD using a range of state-of-the-art scientific 
techniques with integrated bioinformatics. Additional secondary mea-
sures include the study of dietary habits, lifestyle/activity factors and 
symptom burden. 
To characterise and integrate key intrinsic factors multiple ‘omics’ 
approaches (genetic, epigenetic, transcriptomic, metabolomic, pro-
teomic and metagenomic) will be applied to understand inter-in-
dividual variation in severity of hepatic injury, serum and hepatic 
‘omic’ profiles and their interaction with environmental (behavioural/ 
dietary/lifestyle) factors that determine how a patient feels, how the 
disease progresses over time and long term outcomes. We envisage 
these activities will lead to a substantial and definitive atlas of patho-
physiological variation across the spectrum of progressive NAFLD, 
identify predictors of long-term outcome and support identification of 
novel biomarkers and therapeutic targets. 
In terms of application, the present focus of activity for the 
European NAFLD Registry is to support the work of the European Union 
IMI2-funded LITMUS ‘Liver Investigation: Testing Marker Utility in 
Steatohepatitis’ consortium (https://www.imi.europa.eu/projects- 
results/project-factsheets/litmus). This ambitious project brings to-
gether clinicians and scientists from prominent academic centres across 
Europe with companies from the European Federation of 
Pharmaceutical Industries and Associations (EFPIA). Their common 
goals are developing and validating biomarkers for testing NAFLD and 
seeks to establish a defined set of biomarkers that singly or in combi-
nation, enable detection and monitoring of disease progression to/ 
Fig. 2. Overview of the European NAFLD registry governance structure.  
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regression from NAFL through NASH to fibrosis and cirrhosis. Through 
the Registry, research is powered to provide the required clarity on 
biomarker analytical and clinical validity at scale and pace, generating 
the requisite level of high-quality data to support biomarker validation 
and evidence needed for regulatory qualification under the joint EMA 
Committee for Medicinal Products for Human Use (CHMP) and the US 
Food and Drug Administration (FDA) processes. 
2.3. Organisation & oversight 
The European NAFLD Registry operates across multiple territories 
and so a comprehensive organisational and oversight structure has been 
established (Fig. 2) that defines lines of responsibility as well as project 
management, data management, data monitoring and sample handling 
processes. Oversight and recruitment into the Registry are structured 
according to three tiers of geographical hierarchy: central leadership 
and coordination, national oversight and site level delivery. 
Coordination of the study, including establishing the European 
NAFLD Registry Master Protocol, defining standard operating proce-
dures, management of the web-based eCRF database, controlling data 
access and biological sample use are managed centrally by the Registry 
Management Team. This group comprises the Chief Investigator, Study 
Managers, Data Managers, Ethics Lead and representatives from the 
Registry Central Biobank. However, the conduct of the study according 
to these centrally defined processes, including responsibility for study 
sponsorship, regulatory compliance, gaining the necessary national 
and/or local ethical approvals for recruitment and site data-monitoring 
as centrally defined is devolved to a budget-holding National Lead 
Investigator in each country (Table 1). These senior investigators are 
experienced clinical trialists with extensive knowledge of the national 
research frameworks in which they operate. Thus, the Registry is able to 
tailor its activities to varying national research ecosystems whist en-
suring robust data collection in compliance with the International Con-
ference on Harmonisation - Good Clinical Practice (ICH-GCP) require-
ments [18]. 
2.3.1. Ethical practice & regulatory compliance 
All subject recruitment and informed consent processes at recruit-
ment centres are conducted in compliance with nationally accepted 
practice in the respective territory and in accordance with the World 
Medical Association Declaration of Helsinki 2018, the Charter of 
Fundamental Rights of the European Union (2000/C 364/01), and the 
principles defined by the Belmont Report. Data is collected and pro-
cessed in accordance with the applicable General Data Protection 
Regulation (EU) 2016/679 (GDPR) legislation. 
For the ‘LITMUS Study’, a named National Lead Investigator over-
sees the conduct of recruitment at sites in their respective country 
(Table 1). An Ethics Lead curates the central LITMUS Study Trial Master 
File (L-TMF) to ensure all necessary ethical approvals are in place for 
each territory and reports annually to an independent ethics guardian. 
Supplementary Material 1 provides details of the associated ethical 
approvals by country. 
2.3.2. Database 
Personal data including clinical data are collected, and such data are 
protected in accordance with the European General Data Protection 
Regulation (GDPR). Data is held within the Registry in a pseudoano-
nymised (linked-anonymised) form to avoid personally identifiable data 
transfer or processing outside a subject's usual clinical care team at the 
recruiting site. 
A purpose-built MySQL relational database has been developed to 
facilitate data capture during recruitment into the Registry. The web- 
accessible secure front-end database comprises 14 related electronic 
clinical record form (eCRF) data-tables and contains around 1200 data 
fields, equating to approximately 1–2 megabytes of data per subject and 
is designed to fulfil the regulatory requirements for record keeping 
[19]. Data are held in a Clinical Data Interchange Standards Consortium 
(CDISC, www.cdisc.org) compliant format to aid information system 
interoperability for future collaborative projects. The database holding 
the project user records and collected records from sites is hosted on a 
multi-machine replication cluster with multiple physical servers. In the 
event of machine failure or catastrophic data loss, one of the remaining 
database servers would be promoted to become the master server for 
the European NAFLD Registry application. Database records are ar-
chived to a separate physical server three times daily, once per day for 
the previous 31 days and once per month for the previous 12 months. In 
addition, an archive copy of the data is retained on Newcastle Uni-
versity's Research Data Warehouse according to local information se-
curity policy. This ensures a copy of the data is available for up to ten- 
years after the last date of access. Network access to the database is 
controlled by specific role at the individual level. 
Table 2 
Inclusion and Exclusion criteria.    
Criteria  
Inclusion  1. Age ≥ 18 years and able to give informed consent  
2. Clinically suspected NAFLD based on the following:  
A. Historical liver biopsy providing histological evidence of NAFLD or,  
B. Biochemical and/or radiological evidence of NAFLD in patients undergoing liver biopsy or,  
C. Radiological evidence of cirrhosis (in absence of an alternative aetiology) plus ≥2 features of the ‘metabolic syndrome’  
i. Increased waist circumference by ethnically adjusted criteria (e.g. Europid male/female ≥94 cm/80 cm or overweight/obese (BMI ≥ 25 kg/m2);  
ii. Raised fasting glucose ≥100 mg/dL [5.6 mmol/L], HbA1c ≥48 mmol/mol [6.5%] or previously diagnosed insulin resistance/ type 2 diabetes mellitus, or on 
treatment;  
iii. Dyslipidaemia (fasting triglyceride level ≥ 150 mg/dL [1.7 mmol/l]; or fasting high density lipoprotein  < 40 mg/dL [1.03 mmol/l] in males and  <  50 mg/dL 
[1.29 mmol/l] in females, or on treatment;  
iv. Hypertension (systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg), or on treatment. 
Exclusion  1. Refusal or inability to give informed consent  
2. Average alcohol consumption greater than 21/14 units per week (30/20 g/alcohol/day) (males/females) in the preceding 6 months and no history of sustained 
excessive alcohol consumption of alcohol in the past five years.  
3. History or presence of Type 1 diabetes mellitus  
4. Presence of any other form of chronic liver disease  
5. Recent (within 12 months) or concomitant use of agents known to cause hepatic steatosis (long-term systemic corticosteroids [ > 10 days], amiodarone, 
methotrexate, tamoxifen, tetracycline, high dose oestrogens, valproic acid)  
6. Any contraindication to liver biopsy  
7. Recent (within 3 months) change in dose/regimen or introduction of Vitamin E (at a dose of ≥400 IU/day), betaine, s-adenosyl methionine, ursodeoxycholic acid, 
silymarin or pentoxifylline  
8. Non-local language speaker/unable to access interpreter  
9. Patients not meeting the inclusion criteria or judged by the investigator to be unsuitable for inclusion into the study 
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2.3.3. Biorepository 
Biological samples are physically stored in the secure, ISO 9001 
certified and ISO 17025 accredited biobank at the state-of-the-art fa-
cilities of the Integrated BioBank of Luxembourg (IBBL) Institute. 
2.4. Inclusion/exclusion criteria 
The study population is patients aged ≥18 years with risk factors 
for NAFLD that will be recruited in hepatology clinics and/or bariatric 
surgery units primarily distributed at centres across Europe. Patients 
are invited to participate in both the cross-sectional and longitudinal 
aspects of the study but may drop-out of the latter at any point if they 
wish. Two main sources of patients are targeted:  
i. Patients investigated for suspected NAFLD in hepatology clinics, e.g. 
referred for the investigation of abnormal liver biochemistry tests 
noted in primary care.  
ii. Patients seen in bariatric surgery units for planned surgical weight 
loss treatment for morbid obesity. 
Inclusion and exclusion criteria are presented in Table 2. In sum-
mary, for non-cirrhotic patients, confirmation of the diagnosis of 
NAFLD must be made histologically, whereas patients with radiological 
evidence of cirrhosis in the absence of an alternative aetiology may be 
recruited if at least two features indicative of the metabolic syndrome 
are present. Secondary causes of steatosis, including high alcohol con-
sumption, and other coexisting liver diseases are exclusionary. 
2.5. Study procedures 
Study processes have been designed to minimise the burden of 
participation on patients. As much as possible, data and samples are 
collected alongside scheduled routine-care clinical attendance. 
Following signed informed consent, patients are assigned a unique 
‘study participant identification code’ (SPIC). This ensures data are held 
in the Registry in a linked-anonymised form to preserve patient con-
fidentiality. An Investigator Handbook has been developed to assist 
study staff at sites in application of standardised processing methods to 
avoid any centre-related preanalytical bias (Supplementary Material 2). 
2.5.1. Data collection 
A comprehensive dataset is collected from the medical notes at the 
‘baseline’ enrolment clinical attendance (usually coincident with a liver 
biopsy). This detailed dataset includes demographics, anthropometrics, 
a range of clinical (co-morbidities, current medication), laboratory 
(clinical haematology, biochemistry, immunology), histopathological 
and radiological data (Table 3). 
Diagnostic imaging data are collected for all patients undergoing 
clinically indicted investigations. These include routine diagnostic ul-
trasound and Fibroscan™ (vibration-controlled transient elastography 
[VCTE]) as well as any other modalities that may be used as part of 
local practice at recruiting sites. In addition, selected patients are in-
vited to opt-in to participate in a nested imaging study in which MRI- 
PDFF, MR LiverMultiScan™, deMILI, and MR Apparent Diffusion 
Coefficient, as well as elastography (acoustic radiation force impulse 
[ARFI]; and magnetic-resonance elastography [MRE]) are captured out- 
with standard care. 
In addition, the following lifestyle and symptom burden ques-
tionnaires are collected:  
i. Patient-reported health-related quality of life (HRQOL):  
• Chronic Liver Disease Questionnaire for NAFLD NASH (CLDQ 
NAFLD-NASH) [20,21],  • EQ-5D-5L Health [22],  • NASH-CHECK [23].  
ii. Dietary questionnaires:  
• Audit C [24],  • Mediterranean Diet Score [25].  
iii. Lifestyle (exercise/sedentary behaviour assessment):  
• International Physical Activity Questionnaire (IPAQ) [26]. 
Thereafter, ‘follow-up event’ data are collected annually at sched-
uled out-patient clinic attendances. In addition, data collection may be 
triggered if the patient undergoes a subsequent clinically indicated liver 
biopsy or if a significant ‘clinical event’ occurs. Target events are listed 
in Table 4 and focus particularly on death, major adverse cardiovas-
cular events (MACE), hepatic events (progression to cirrhosis, hepatic 
decompensation and/or HCC) and extra-hepatic malignancy. 
Where healthcare systems permit (for example, the UK's National 
Health Service “NHS Digital” platform), patients are asked to allow 
their national health records to be flagged to facilitate capture of long- 
term outcome events if they are lost to follow up at the recruitment site. 
Table 3 
Summary of clinical data collected at enrolment and follow-up events.   
Categories of data  
Basic data   
• Date of Birth and Age at event  • Sex at Birth  • Self-reported ethnicity  • Anthropometrics:  
o Height (cm)  
o Weight (kg)  
o Waist circumference (cm)  
o Hip circumference (cm) 
Medical history   
• Relevant comorbidities, including:  
o Hypertension, Dyslipidaemia, Type 2 Diabetes  
o Obstructive sleep apnoea  
o Malignancy  
o Cardiovascular disease/Stroke  
o Other relevant  • Current/Recent medication (including over-the-counter and traditional/herbal 
remedies)  • Participation in any therapeutic clinical trials 
Results of clinical investigations   
• Results of local histopathological assessments of liver biopsy.  • Results of routine Haematology, Clinical Biochemistry, Immunology, and Virology 
investigations (all with date of sample collection)  
o The following should be collected within ± 30 days of liver biopsy and in a 
fasting condition:  
▪ Haematology (FBC, Clotting)  
▪ Clinical Biochemistry (U&E, LFTs [Alb, Bili, ALP, ALT, AST, gGT], Ferritin/ 
Transferrin saturation, HBA1C, Glucose, Insulin, C-peptide, TSH, Lipid profile)  
▪ Biomarkers (if available, e.g. CK18, ELF)  
o The following are not time limited:  
▪ Viral serology (HBV, HCV)  
▪ Auto-antibody screen, Immunoglobulins (IgG, IgA, IgM)  
▪ A1AT, Copper/Caeruloplasmin  • Ultrasound imaging  • Ultrasound based Elastography (e.g. Fibroscan [Transient Elastography/CAP], 
ARFI, SuperSonic Imaging) 
Lifestyle   
• Average alcohol intake (units/week) for last 6 months as a quantitative variable  • Alcohol intake – any history of alcohol excess?  • Smoker – Yes/No/Ex  • Tea/Coffee consumption – cups/day  • Social factors including employment and education status 
Family history   
• Limited family medical history (first degree relatives) 
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In addition, if a patient were to move their regular care provider from 
one participating centre to another, the patient can transfer their un-
ique SPIC to the new participating site so that the new site can continue 
to update the patient's registry record. 
2.5.2. Sample Collection & Processing 
Following informed consent and study code (SPIC) assignment, 
patients provide biological samples for research use at enrolment 
(baseline). Blood samples are drawn in the fasted state as close to the 
date of the liver biopsy as possible ( ± 30 days). Collected biological 
samples include: whole blood for serum and plasma isolation, for 
genomic DNA extraction, then for circulating miRNA and circulating 
cfDNA extraction from plasma; stool for microbial DNA extraction; 
urine; and liver tissue (formalin-fixed, paraffin embedded [FFPE] and 
snap-frozen samples), if the patient is undergoing a clinically indicated 
liver biopsy. Samples to be collected are summarised in Fig. 3, which 
provides an overview of how samples are processed and transferred to 
the central biobank facility. Faecal microbiome analyses are known to 
be significantly impacted by different DNA extraction methods, there-
fore all stool DNA extractions are centrally performed at the IBBL with a 
Table 4 
Key clinically significant events targeted during follow-up.    
Event category  
Death⁎ 
Major Adverse 
Cardiovascular Events  
1. Non-fatal Stroke (CVA)  
2. Non-fatal myocardial infarction (‘STEMI’ or 
‘Non-STEMI’)  
3. Coronary revascularisation (angioplasty, CABG)  
4. Hospitalisation for heart failure 
Hepatic  1. Diagnosis of cirrhosis  
2. Diagnosis of varices at endoscopy  
3. Variceal haemorrhage  
4. Hepatic decompensation (jaundice, ascites, 
encephalopathy – including commencement of 
treatment for encephalopathy or ascites)  
5. Hepatocellular carcinoma  
6. Liver transplantation 
Other  1. Diagnosis of extra-hepatic malignancy  
2. Emergency hospitalisation 
⁎ In the event of death, cause of death is recorded.  
Fig. 3. Summary of biological sample collection processing. 
At enrolment (Baseline) and at subsequent annual follow-up visits, or if a clinically significant event occurs, a range of samples will be collected from patients 
participating in The European NAFLD Registry. These will be processed according to defined SOPs and shipped to the Central Biobank facility for storage. 
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validated method [27]. At subsequent annual routine hospital atten-
dances or major clinical events, patients are asked to provide follow-up 
biological samples for longitudinal studies. To ensure high quality 
samples are consistently collected across all sites and to minimise pre- 
analytical variation, standard operating procedures have been estab-
lished and are fully described in the Investigator Handbook (Supple-
mentary Material 2). 
2.5.3. Central histological interpretation & digitisation of liver biopsies 
Histopathological assessment of liver biopsy remains the widely 
accepted, albeit imperfect, reference standard for assessing severity of 
liver disease [28]. As well as issues with sampling error [29], there 
remain concerns regarding potential interobserver variability in as-
sessment. To address these issues, the European NAFLD Registry has 
adopted a number of measures to ensure data quality:  
i. Histology Processing at a Central Laboratory. To minimise variation in 
slide staining between laboratories, biopsies are fixed in 10% buf-
fered formalin, embedded in paraffin and cut into 3–4 μm sections 
at recruitment sites. Four unstained slides are then shipped to the 
Central Biobank for staining, digitisation and storage. At IBBL, 
slides are stained with haematoxylin and eosin (H + E) and 
Masson's trichome for collagen according to established standard 
operating procedures. Then high-resolution digitised images are 
captured using the CaloPix® platform (Tribvn Healthcare, France).  
ii. Semiquantitative histological scoring systems are used to standardise 
reading of biopsies. Grade of steatosis/steatohepatitis are reported 
according to both the well validated NASH Clinical Research 
Network (CRN) “NAFLD Activity Score” (NAS) and the FLIP 
“Steatosis – Activity – Fibrosis” (SAF) systems [30,31]. Whilst these 
scoring systems differ in important ways, all measure four key his-
tological characteristics: grade of steatosis, severity of hepatocel-
lular injury (hepatocyte ballooning) and lobular inflammation, and 
stage of fibrosis (summarised in Table 5). Fibrosis stage is recorded 
using both the NASH CRN/SAF 5-tier (F0-4) and the EPoS 7-tier (F0- 
6) fibrosis staging systems (including sub-staging of cirrhosis into 
stages 6a, 6b and 6c according to modified Laennec staging) 
[32,33]. In addition to histological scoring of these standard fea-
tures, pathologists also assess the intensity of portal inflammation, 
the presence of Mallory-Denk bodies and determine a broad diag-
nostic category (i.e. normal, NAFL, definite NASH, fibrosis/cirrhosis 
without steatosis consistent/not consistent with NAFLD). All data 
are captured using a standardised reporting proforma. 
iii. The Registry Histopathology Group (RHG) comprises ten expert he-
patopathologists (Table 6) who participate in a face-to-face har-
monisation meetings to align on histological criteria and have de-
monstrated close interobserver concordance [31]. Pairs of 
hepatopathologists from this group independently double-score 
liver biopsies with reference to a digital atlas of NAFLD histology 
that has been prepared by the group leaders (Supplementary Ma-
terial 3 and via the European Society of Pathology website: https:// 
tinyurl.com/LITMUS-Histology). If the two scores within a pair are 
found to be discrepant (by ≥2 points for steatosis or inflammation, 
and ≥ 1 for ballooning or fibrosis) the biopsy is referred to a con-
sensus adjudication panel. To further ensure data quality, the ad-
judication panel reviews a random sample of biopsies for quality 
control. An administrator assigns the liver biopsies to the patholo-
gist pairs, completes the final report for each case based on the 
agreed scores and uploads the histological data in the NAFLD 
Registry. 
Although semiquantitative scoring systems are used in many clinical 
trials [34–38], it is recognised that scoring systems provide a non- 
linear, semiquantitative or categorical assessment of disease that may 
limit precision and granularity of data, particularly in the context of 
subtle changes over time or at the boundary between two categories, 
where misclassification may occur. To supplement these efforts, the 
European NAFLD Registry also captures data from a number of novel 
automated quantitative assessment measures based on digitised biopsy 
images and second harmonic generation/two-photon excitation mi-
croscopy (Genesis200®, HistoIndex, Singapore), leveraging machine 
learning and artificial intelligence approaches to add further value to 
Table 5 
Comparison of the SAF Score and the NAFLD Clinical Research Network Score for the histological grading and staging of NAFLD.        
SAF score [42] NASH CRN NAFLD activity score [30] 
Histological feature Category definition Histological feature Category definition  
Steatosis† 0 
1 
2 
3  
< 5% 
5–33% 
34–66%  
> 66% 
Steatosis‡ 0 
1 
2 
3  
< 5% 
5–33% 
34–66%  
> 66% 
(S) Steatosis Score 0–3 PLUS 
Hepatocyte Ballooning 0 
1 
2 
None 
Clusters of hepatocytes with rounded shape and pale and/or reticulated 
cytoplasm 
Same as grade 1 with enlarged hepatocytes (> 2× normal size) 
Hepatocyte Ballooning 0 
1 
2 
None 
Few 
Many 
PLUS PLUS 
Inflammation 0 
1 
2 
None 
≤ 2 foci per 20× field  
>  2 foci per 20× field 
Inflammation 0 
1 
2 
3 
None 
≤2 foci per 20× field 
2–4 foci per 20× field  
> 4 foci per 20× field 
(A) Total = Activity Score 0–4⁎ (NAS) Total = NAFLD Activity Score 0–8 
Fibrosis 0 
1a 
1b 
1c 
2 
3 
4 
No significant fibrosis 
Zone 3 mild perisinusoidal fibrosis 
Zone 3 moderate perisinusoidal fibrosis 
Periportal/portal fibrosis only 
Zone 3 plus portal/periportal fibrosis 
Bridging fibrosis 
Cirrhosis 
Fibrosis 0 
1a 
1b 
1c 
2 
3 
4 
No significant fibrosis 
Zone 3 mild perisinusoidal fibrosis 
Zone 3 moderate perisinusoidal fibrosis 
Periportal/portal fibrosis only 
Zone 3 plus portal/periportal fibrosis 
Bridging fibrosis 
Cirrhosis 
(F) Fibrosis Score 0–4 Fibrosis Score 0–4 
† Percentage of parenchymal involvement by steatosis. 
‡ Percentage of hepatocytes containing large and/or medium-sized intracytoplasmic lipid droplets. 
⁎ SAF A1 (A = 1): mild activity; A2 (A = 2): moderate activity; A3 & A4 (A  >  2): severe activity. Table adapted from [28,43].  
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the dataset [39]. 
2.5.4. Data monitoring 
Monitoring is a crucial quality control process to establish that study 
activities are being carried out as intended, so that deficiencies can be 
addressed, and is critical to the protection of human subjects, the 
conduct of high-quality studies and the generation of robust clinical 
trial data. [40]. The European NAFLD Registry has adopted a risk-based 
monitoring approach as recommended by the FDA in its guidance 
document Oversight of Clinical Investigations – A Risk-Based Approach to 
Monitoring (August 2013) [40,41]. This dynamic, iterative process fo-
cuses oversight activities on preventing or mitigating important and 
likely risks to data quality and trial integrity. Thus, findings determine 
subsequent actions (for example, targeted additional training of clinical 
investigators at sites, clarification of protocol requirements) to ensure 
the requisite levels of data quality are achieved. Due to the non-inter-
ventional nature of the Registry, risk-assessment has determined that 
the likelihood of direct harm to participants is minimal and so mon-
itoring primarily focusses on ensuring that conduct is in compliance 
with the protocol and that study data are complete, accurate and ver-
ifiable. In line with the organisational structure of the Registry, mon-
itoring activities are structured as three tiers: central oversight of data 
integrity, country-level source-data verification checks with external 
monitors visiting sites and site-level internal data checks conducted by 
the local research teams. 
Central monitoring is conducted by the central Registry 
Management Team (Fig. 2). Central data managers perform consistency 
checks of data entered into the Registry at least every 6 months. These 
include review of enrolment rates against site and study targets; data 
validation for completeness and plausibility; and oversight of mon-
itoring activities. Any inconsistencies, errors or omissions detected are 
flagged to the recruiting site to address. The Registry Management 
Team and Central Biobank also oversees biological sample management 
and cross-referencing of the biobank catalogue with the Registry da-
tabase to ensure samples are received and logged appropriately. 
At the country level, National Clinical Leads serve as the national 
chief investigator in their territory and are responsible for compliance 
and on-site monitoring. The National Clinical Leads carry out Site 
Initiation visits providing information to sites on study background, 
protocol, and data management procedures. Inconsistencies, errors or 
omissions flagged by the Registry Management Team are highlighted to 
the National Clinical Lead who ensures the recruiting site checks and 
amends errors as necessary. A key role of the National Clinical Lead is 
to appoint site monitors to ensure compliance with GCP, data con-
sistency across sites in a territory and appropriateness of training. Site 
monitoring includes several important activities, but crucially source 
data verification (SDV). A first monitoring visit is conducted at each site 
within three months of the first subject enrolled into the European 
NAFLD Registry, once per year of the study and until three months after 
the recruitment of the last subject. Briefly, the first two participants in 
the study are subject to 100% SDV through the entirety of the project; if 
major errors/critical findings are found in these patients, the sub-
sequent two patients recruited will follow the same monitoring proce-
dure through the study. Additional activities include review of signed 
consent forms for all participants and authority approvals are in place. 
The final layer of oversight comes at a site-level. Site level mon-
itoring is carried out by an independent member of the local research 
team, not the individual who entered the data, and includes con-
firmation of consent, data collection according to study protocol and 
ensuring complete datasets. Protocol deviations are documented in 
each participant record using the protocol deviation form and reported 
to the National Clinical Lead. Internal monitoring tasks include checks 
that: all participants are consented on the most up-to-date, approved 
informed consent form in effect at their last visit and that all forms have 
been completed correctly and the consent date entered into the 
Registry; data being collected is consistent with what is required by the 
study protocol and an accurate transcription of the source documents, 
with special attention being paid to accuracy of reported clinical events 
and associated investigations. 
2.6. Data management 
The European NAFLD Registry has a comprehensive data manage-
ment plan (DMP) to allow secure management of generated data sets 
and plans for publications, data access and preservation policies. The 
DMP will be regularly updated to reflect other data sets that may be 
developed within the European NAFLD Registry, which aims to provide 
accurate and high-quality data to the research community, so that the 
Registry will contribute to future advancements in the field of advanced 
diagnostics. Dissemination of research data is planned in the form of 
publications in scientific journals and/or presented in scientific or other 
meetings for the benefit of the wider medical community. Participants 
will not be identifiable from such published data nor in any datasets 
that may be placed in the public domain. 
3. Discussion 
The European NAFLD Registry represents a major international ef-
fort involving leading secondary/tertiary care centres in Europe, to 
prospectively recruit patients into an observational study exploring the 
pathophysiology of progressive liver disease, disease outcomes and 
associated predictive factors in patients with NAFLD. Importantly, data 
generated from this study will address key unmet medical needs: the 
European NAFLD Registry underpins the LITMUS consortium goal of 
establishing a defined set of biomarkers that singly or in combination, 
enable detection and monitoring of disease progression to/regression 
Table 6 
Organisation of the Registry Histopathology Group: pairing and adjudication panel.     
Pathologist pair number Pathologist Institution  
1 Johanna Arola University of Helsinki, Helsinki, Finland 
Pierre Bedossa LiverPat, Paris, France; Translational & Clinical Research Institute, Newcastle University, UK 
2 Susan Davies Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK 
Dina Tiniakos Translational & Clinical Research Institute, Newcastle University, UK; Medical School, National and Kapodistrian University of 
Athens, Greece 
3 Stefan Hübscher Queen Elizabeth Hospital, University of Birmingham, UK 
Valerie Paradis Hôpital Beaujon, Université Paris-Diderot, Paris, France 
4 Beate Straub Institute of Pathology, University Medical Centre Mainz, Mainz, Germany 
Joanne Verheij Amsterdam University Medical Centre, The Netherlands 
5 Alastair Burt Translational & Clinical Research Institute, Newcastle University, UK 
Ann Driessen University of Antwerp, Antwerp, Belgium 
Adjudication Panel Dina Tiniakos Translational & Clinical Research Institute, Newcastle University, UK; Medical School, National and Kapodistrian University of 
Athens, Greece 
Pierre Bedossa LiverPat, Paris, France; Translational & Clinical Research Institute, Newcastle University, UK 
T. Hardy, et al.   Contemporary Clinical Trials 98 (2020) 106175
9
from NAFL through NASH to fibrosis and cirrhosis that may be used in 
clinical trials. 
The European NAFLD Registry seeks to cognise the variability in 
NAFLD disease course by leveraging large sets of integrated ‘-omic’ data 
to better understand the pathophysiological processes that underpin 
NAFLD disease severity and progression. It also collates existing pro-
spectively recruited cohorts to permit better granularity of disease 
outcomes. Together, the European NAFLD Registry data set will allow 
better correlation of biomarkers with disease diagnosis, prognosis and 
monitoring, permitting the advent of new pharmacotherapy, which is 
desperately needed. 
The strengths of the Registry are its large sample size, international 
recruitment, standardised procedures, and fastidious data monitoring 
plans. The Registry aims not only to collect data of the highest quality, 
but also to have the ability to prove that the data is of the utmost 
veracity. Built within the Registry is a geographical hierarchy that fa-
cilitates implementation of a clinical monitoring plan that ultimately 
verifies the high quality of the data collected. A unique strength of the 
Registry is its ability to provide integrated datasets of both cross sec-
tional and longitudinal analysis in the same patient to ascertain causal 
relationships and mechanisms in disease progression. This capability 
will facilitate unsupervised data exploration and analysis to develop 
novel research hypothesis by artificial intelligence/machine learning in 
addition to end-user directed hypothesis testing. With approved phar-
macotherapies for NASH likely to become available in the near future, 
the European NAFLD Registry platform also has the capability to sup-
port authority requested post-marketing surveillance studies (post-au-
thorisation safety and/or efficacy studies); facilitating the systematic 
monitoring of medications while they are used in clinical practice. 
In summary, the European NAFLD Registry is a comprehensive 
study using standardised data collection practises, clinical monitoring 
plans and observational protocols to garner the highest quality, large 
datasets that can be leveraged to better understand and ultimately 
develop biomarkers across the spectrum of NAFLD severity that can 
lead to efficient drug discovery and regulatory approval- a key unmet 
need in NAFLD management. The Registry will facilitate research at 
scale and pace, with rapid dissemination of research findings to im-
prove patient management and outcomes. 
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